Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12812860 | 0.83 | CYP2C9 (0.54) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5372083 | 0.80 | CYP2C9 (0.65) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL18255787 | 0.80 | TTR (0.57) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL2260952 | 0.79 | KDM1A (0.56) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14691464 | 0.79 | CYP2C9 (0.49) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31418275 | 0.78 | CYP2C9 (0.55) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14589039 | 0.78 | DPP4 (0.39) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL31418164 | 0.78 | CYP2C9 (0.51) | CYP2C9CYP2C19MAPTIMPDH2CTSA | |
| SCHEMBL1895643 | 0.78 | CYP2C9 (0.57) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15830643 | 0.77 | CYP2C9 (0.54) | CYP2C9CYP2C19SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | disclosed |
| US-6235758-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-5990133-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | HTR5A, HTR2C, HTR1A | CYP2C9 582/4885CYP2C19 344/4885SMN1; SMN2 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.